Sweden Pharmaceuticals & Healthcare Report Q1 2015

Nov 7, 2014 - Business Monitor International - 122 pages - USD $1,295
Abstract Table of Contents Request Details Related
Declining government reimbursement for prescription medicines does not bode well for innovative drugmakers selling their products in Sweden, particularly as the government is the primary purchaser of pharmaceuticals. Furthermore, over the long term, pushing costs onto a population with fewer young people to financially support the elderly will ultimately work to reduce the consumption of higher-value innovative pharmaceuticals.

Headline Expenditure Projections
  • Pharmaceuticals: SEK36.28bn (USD5.70bn) in 2013 to SEK36.41bn (USD5.36bn) in 2014; +0.38% in local currency terms and -5.9% in US dollar terms.
  • Healthcare: SEK351.16bn (USD55.18bn) in 2013 to SEK356.95bn (USD52.56bn) in 2014; +1.6% in local currency terms and -4.7% in US dollar terms.
Risk/Reward Index: We continue to view Sweden as a moderately attractive regional market. On the positive side, factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this small market of fewer than 10mn people.

Key Trends And Developments

Sweden has the best healthcare system to deal with diabetes of all the EU member states, including Norway and Switzerland, as it has a better national registry, according to the 2014 Euro Diabetes Index launched in Vienna. Sweden was followed by the Netherlands, Denmark and the UK, while Bulgaria, Lithuania and Estonia scored lowest. The analysis, which came from the Health Consumer Powerhouse (HCP), was based on 28 defined indicators and areas, including prevention, case finding, range and reach of services, access to treatment and care, procedures and outcomes. Sweden only needs to improve its prevention under 'Exercise in compulsory school', according to the HCP.

About 850,000 false prescriptions are corrected by pharmacies every year in Sweden,...


Order This Report
FORMAT: PDF - Download Now with 3 Quarterly Updates $1,295 USD
LICENSE: Single-User
DELIVERY: Instant Download

EASY ORDERING
Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.